Use of mtor inhibitor mtt-1 in anti-aging cosmetics

Abstract

The application relates to the technical field of daily chemicals, and discloses application of an mTOR inhibitor MTT-1 in anti-aging cosmetics, which comprises the following steps: introducing the mTOR inhibitor MTT-1 with a mass percentage concentration of 0.01% to 5.0% into a cosmetic matrix in a homogenizing device, controlling the material temperature to be 35 DEG C to 45 DEG C, blending and dispersing the components, and adjusting the pH value of the system to be 5.0 to 7.5 to prepare an anti-aging cosmetic preparation; and coating the anti-aging cosmetic preparation on the surface of skin to establish a first concentration enrichment zone and a second concentration enrichment zone. The application utilizes a two-phase regulation mechanism, overcomes the toxic and stimulating side effects of a classical inhibitor on skin cells, removes active oxygen and inflammatory factors, and improves the collagen level in a dermis layer, so that the proliferation activity of aged skin cells is recovered on the premise of eliminating tissue stimulation.

Description

Technical Field

[0001] This invention relates to the application of an mTOR inhibitor, MTT-1, in anti-aging cosmetics, belonging to the field of daily chemical products technology. Background Technology

[0002] Currently, blocking the phosphorylation activation of mammalian target of rapamycin with molecules of specific activity, thereby relieving the inhibition of the autophagy core complex and mobilizing the cellular autophagy program to clear damaged intracellular components, constitutes the mainstream pathway for improving the deterioration of the epidermal cell microenvironment and restoring the vitality of dermal cells. This molecular pathway has shown definite technical value in regulating collagen expression levels and restoring cell proliferation capacity. The actual efficacy of such topical skin interventions is highly dependent on the ability of active molecules to penetrate the stratum corneum of the epidermis and the dispersion stability of molecules in the epidermal lipid interface. However, classic pathway inhibitors often have macrolide core structures. These macromolecules have significant steric hindrance and strong molecular polarity, making them more likely to stagnate outside the inherent lipid barrier. At the same time, when introduced into complex cosmetic formulations containing emulsifiers, stabilizers, emollients, and polyols, they often cause thermodynamic compatibility degradation, resulting in compatibility barriers such as crystallization and degradation failure.

[0003] To overcome the technical problems of low penetration efficiency and unstable formulation systems, blindly increasing the dosage or using excessive penetration enhancers in a linear manner can easily trigger strong local cytotoxic damage, leading to the collapse of the epidermal barrier structure. This phenomenon, which pursues specific target inhibition efficacy but inevitably degrades skin cell safety and formulation thermodynamic compatibility, constitutes a fundamental constraint that is difficult to overcome when this intervention pathway is transformed into a mild topical formulation. In addition to the aforementioned limitations in the thermodynamic compatibility of the formulation system at the static level, the transdermal diffusion controlled release method of the topical intervention during the dynamic application and retention process on the face also has shortcomings. For example, Chinese invention patent application with publication number CN114585350A discloses a formulation containing... Topical rapamycin formulations, by solubilizing macrolide rapamycin with specific weight ratios of ethylene glycol salicylate, propylene glycol, or polyethylene glycol, can improve the preservation stability and transfer rate to the dermis to some extent. However, when faced with the dynamic high resistance of the facial epidermis and the tissue metabolic depletion during continuous administration, a static, single solvent ratio cannot induce a progressive concentration buildup within the formulation. This results in the active ingredient rapidly decaying during transdermal penetration due to tissue barrier depletion, making it difficult to maintain a high, elastic autophagy-based concentration around fibroblasts. This lack of an active counteracting mechanism for transdermal diffusion limits the reversal efficacy against collagen expression levels in the dermis when applied to the face for extended periods.

[0004] Therefore, the technical problem to be solved by this invention is how to provide a specific chromone small molecule that has good permeability to the skin barrier, low irritation to skin cells, and high compatibility in complex formulation matrices. Summary of the Invention

[0005] To address the problems in the background art, the technical solution of the present invention is as follows: The application of the mTOR inhibitor MTT-1 in anti-aging cosmetics includes the following steps: Step S1: In a homogenizing device, an mTOR inhibitor MTT-1 with a mass percentage concentration of 0.01% to 5.0% is introduced into the cosmetic matrix. The material temperature is controlled at 35°C to 45°C, the homogenization shear rate is controlled at 2000 rpm to 4000 rpm, and the stirring speed is controlled at 200 rpm to 500 rpm. The components are blended and dispersed, and a pH adjuster is added to adjust the pH of the system to 5.0 to 7.5 to obtain an anti-aging cosmetic formulation. The cosmetic matrix is ​​composed of emulsifiers, stabilizers, emollients, polyols, and deionized water. Step S2, dissolve the anti-aging cosmetic preparation at 0.5 mg / cm³. 2 Up to 2.0 mg / cm 2 A single dose applied to the surface of the facial skin penetrates the lipid channels of the stratum corneum and diffuses into the dermis, allowing the mTOR inhibitor MTT-1 to diffuse in the extracellular matrix microenvironment of the dermis and surround fibroblasts and keratinocytes, establishing a first concentration enrichment zone around fibroblasts and keratinocytes. Step S3 involves continuously applying the anti-aging cosmetic preparation to the surface of the facial skin in a 24-hour cycle, applying it once or twice per cycle. Through continuous administration, a progressive concentration accumulation is induced within the skin tissue, establishing a second concentration enrichment zone in the dermis that is higher than the first concentration enrichment zone. This counteracts tissue loss during transdermal penetration of the anti-aging cosmetic preparation and increases the content of type I and type III collagen in the dermis.

[0006] Preferably, in step S1, the cosmetic matrix comprises the following components by weight: 1.0 to 5.0 parts of emulsifier, 0.5 to 3.0 parts of stabilizer, 5.0 to 20.0 parts of emollient, 3.0 to 15.0 parts of polyol, and deionized water to make up to 100.0 parts; during the blending and dispersion, the material temperature is controlled within the range of 38°C to 42°C, and the pH of the system is adjusted to 5.5 to 6.5 to improve the thermodynamic compatibility of the anti-aging cosmetic formulation in alternating hot and cold environments.

[0007] Preferably, step S2 includes the following sub-steps: step S21, applying the anti-aging cosmetic preparation to the surface of the facial skin, allowing the mTOR inhibitor MTT-1 in the anti-aging cosmetic preparation to penetrate the stratum corneum of the skin surface and enter the epidermis and dermis; step S22, allowing the mTOR inhibitor MTT-1 that has entered the dermis to diffuse in the extracellular matrix of the dermis and distribute around fibroblasts and keratinocytes, establishing a first concentration enrichment zone.

[0008] Preferably, the emulsifiers include potassium cetyl phosphate and glyceryl stearate, the polyols include glycerin, butylene glycol and propylene glycol, the stabilizers include xanthan gum and carbomer, and the emollients include squalane, jojoba seed oil and pentaerythritol tetraester; in step S1, the homogenization shear rate is controlled at 2000 rpm to 4000 rpm, and the average particle size of the mTOR inhibitor MTT-1 in the cosmetic matrix is ​​controlled in the range of 100 nm to 500 nm.

[0009] Preferably, step S3 includes the following sub-steps: Step S31, applying the anti-aging cosmetic preparation to the surface of the facial skin continuously at a 24-hour cycle, applying it once or twice per cycle, so that the mTOR inhibitor MTT-1 in the dermis is maintained in the second concentration enrichment zone during the continuous administration cycle of 28 days to 56 days; Step S32, under the effect of the concentration in the second concentration enrichment zone, increasing the levels of type I collagen and type III collagen in the dermis.

[0010] Preferably, during the continuous application of the anti-aging cosmetic preparation to the surface of the facial skin, the method further includes periodically measuring the elastic modulus of the skin surface using a skin elasticity tester, calculating the rate of change of the elastic modulus over time, and when the rate of change decreases to 0, adjusting the application cycle of the anti-aging cosmetic preparation from twice every 24 hours to once every 24 hours.

[0011] Preferably, the anti-aging cosmetic formulation has chicken embryo chorioallantoic membrane safety and in vitro cell safety. In the chicken embryo chorioallantoic membrane contact test, the contact time of the test solution with a mass percentage concentration of 3.125% is controlled at 5 min, and its irritation score is 0.00 with no vascular bleeding, no vascular dissolution, and no coagulation. In the in vitro cell toxicity test, the in vitro cell survival rate of fibroblasts and keratinocytes after 48 h of contact with the anti-aging cosmetic formulation is greater than or equal to 95%.

[0012] Preferably, the anti-aging cosmetic formulation has physicochemical stability. After being placed in a high-temperature environment of 40°C, a low-temperature environment of -10°C, and a strong light irradiation environment with a wavelength of 300nm to 400nm for 30 consecutive days, the purity of the mTOR inhibitor MTT-1 was found to be greater than or equal to 98% by high-resolution mass spectrometry and nuclear magnetic resonance spectroscopy. The anti-aging cosmetic formulation also maintained an emulsion state without crystal precipitation or discoloration.

[0013] Preferably, the anti-aging cosmetic formulation has different product form configurations: in the form of a face cream, the mass percentage of polyol in the anti-aging cosmetic formulation is 8.0% to 15.0%, and the apparent viscosity of the system is maintained in the range of 10 Pa·s to 20 Pa·s; in the form of a serum, the mass percentage of polyol in the anti-aging cosmetic formulation is 3.0% to 7.9%, and the apparent viscosity of the system is maintained in the range of 1 Pa·s to 5 Pa·s.

[0014] Compared with the prior art, the beneficial effects of the present invention are: 1. In anti-aging cosmetics, this invention uses chromone compounds obtained through structural modification to replace the traditional macrolide core. The planar conjugation characteristics of these molecules enhance their dispersion ability and thermodynamic stability at the lipid interface, making them easier to penetrate the epidermal barrier and uniformly delivered to the dermis. By enhancing the specific recognition of kinase catalytic sites, it achieves precise regulation of cell signaling pathways, thereby avoiding local barrier damage caused by excessive inhibition or non-specific binding of traditional inhibitors. While ensuring the anti-aging regulatory effect, it reduces skin cell toxicity under topical conditions, providing a stable molecular structure guarantee for long-term skin-residual cosmetic formulation systems.

[0015] 2. This invention utilizes a concentration-dependent biphasic regulatory mechanism to balance the activation state of skin cells. When administered at low doses, it acts on intracellular antioxidant and anti-inflammatory pathways, blocking the accumulation of reactive oxygen species and the release of inflammatory factors to maintain mitochondrial homeostasis and prevent aging-related secretory phenotypes from causing cascading damage to surrounding cells. When the drug concentration is increased, the higher dose condition blocks the phosphorylation activation state of the kinase cascade axis, relieves the inhibition of the autophagy core complex and initiates the autophagy degradation program, clearing damaged intracellular components and denatured proteins, thereby restoring the proliferative vitality of skin cells in a state of aging stagnation, achieving the regulatory effect of improving the cellular microenvironment and reversing autophagy.

[0016] 3. The chromone compounds involved in this invention exhibit superior physicochemical stability and formulation compatibility compared to traditional skincare raw materials that are prone to oxidation and hydrolysis due to their stable internal electronic conjugation effect. When introduced into leave-on or rinse-off cosmetic formulation matrices containing emulsifiers, stabilizers, emollients, and polyols, they can maintain good thermodynamic compatibility within a set range of alternating hot and cold environments and pH levels, avoiding crystallization, discoloration, or degradation. This allows high-concentration active ingredients to be stably dispersed in the formulation system for a long period, reducing dispersion barriers during the industrial-scale production of complex skincare products and demonstrating good commercialization feasibility. Attached Figure Description

[0017] Figure 1 This is a flowchart illustrating the preparation and transdermal penetration process of the anti-aging cosmetic formulation of the present invention. Figure 2 This diagram illustrates the action of the mTOR inhibitor MTT-1 in skin tissue according to the present invention.

[0018] The objectives, features, and advantages of this invention will be further explained in conjunction with the embodiments and with reference to the accompanying drawings. Detailed Implementation

[0019] The technical solutions of the embodiments of this application will be clearly described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this application, not all embodiments. All other embodiments obtained by those skilled in the art based on the embodiments of this application are within the scope of protection of this application.

[0020] The application of an mTOR inhibitor, MTT-1, in anti-aging cosmetics includes the following steps: Step S1: In a homogenizing device, an mTOR inhibitor MTT-1 with a mass percentage concentration of 0.01% to 5.0% is introduced into the cosmetic matrix. The material temperature is controlled at 35°C to 45°C, the homogenization shear rate is controlled at 2000 rpm to 4000 rpm, and the stirring speed is controlled at 200 rpm to 500 rpm. The components are blended and dispersed, and a pH adjuster is added to adjust the pH of the system to 5.0 to 7.5 to obtain an anti-aging cosmetic formulation. The cosmetic matrix is ​​composed of emulsifiers, stabilizers, emollients, polyols, and deionized water. Step S2, dissolve the anti-aging cosmetic preparation at 0.5 mg / cm³. 2 Up to 2.0 mg / cm 2A single dose applied to the surface of the facial skin penetrates the lipid channels of the stratum corneum and diffuses into the dermis, allowing the mTOR inhibitor MTT-1 to diffuse in the extracellular matrix microenvironment of the dermis and surround fibroblasts and keratinocytes, establishing a first concentration enrichment zone around fibroblasts and keratinocytes. Step S3 involves continuously applying the anti-aging cosmetic preparation to the surface of the facial skin in a 24-hour cycle, applying it once or twice per cycle. Through continuous administration, a progressive concentration accumulation is induced within the skin tissue, establishing a second concentration enrichment zone in the dermis that is higher than the first concentration enrichment zone. This counteracts tissue loss during transdermal penetration of the anti-aging cosmetic preparation and increases the content of type I and type III collagen in the dermis.

[0021] Preferably, in step S1, the cosmetic matrix comprises the following components by weight: 1.0 to 5.0 parts of emulsifier, 0.5 to 3.0 parts of stabilizer, 5.0 to 20.0 parts of emollient, 3.0 to 15.0 parts of polyol, and deionized water to make up to 100.0 parts; during the blending and dispersion, the material temperature is controlled within the range of 38°C to 42°C, and the pH of the system is adjusted to 5.5 to 6.5 to improve the thermodynamic compatibility of the anti-aging cosmetic formulation in alternating hot and cold environments.

[0022] Preferably, step S2 includes the following sub-steps: step S21, applying the anti-aging cosmetic preparation to the surface of the facial skin, allowing the mTOR inhibitor MTT-1 in the anti-aging cosmetic preparation to penetrate the stratum corneum of the skin surface and enter the epidermis and dermis; step S22, allowing the mTOR inhibitor MTT-1 that has entered the dermis to diffuse in the extracellular matrix of the dermis and distribute around fibroblasts and keratinocytes, establishing a first concentration enrichment zone.

[0023] Preferably, the emulsifiers include potassium cetyl phosphate and glyceryl stearate, the polyols include glycerin, butylene glycol and propylene glycol, the stabilizers include xanthan gum and carbomer, and the emollients include squalane, jojoba seed oil and pentaerythritol tetraester; in step S1, the homogenization shear rate is controlled at 2000 rpm to 4000 rpm, and the average particle size of the mTOR inhibitor MTT-1 in the cosmetic matrix is ​​controlled in the range of 100 nm to 500 nm.

[0024] Preferably, step S3 includes the following sub-steps: Step S31, applying the anti-aging cosmetic preparation to the surface of the facial skin continuously at a 24-hour cycle, applying it once or twice per cycle, so that the mTOR inhibitor MTT-1 in the dermis is maintained in the second concentration enrichment zone during the continuous administration cycle of 28 days to 56 days; Step S32, under the effect of the concentration in the second concentration enrichment zone, increasing the levels of type I collagen and type III collagen in the dermis.

[0025] Preferably, during the continuous application of the anti-aging cosmetic preparation to the surface of the facial skin, the method further includes periodically measuring the elastic modulus of the skin surface using a skin elasticity tester, calculating the rate of change of the elastic modulus over time, and when the rate of change decreases to 0, adjusting the application cycle of the anti-aging cosmetic preparation from twice every 24 hours to once every 24 hours.

[0026] Preferably, the anti-aging cosmetic formulation has chicken embryo chorioallantoic membrane safety and in vitro cell safety. In the chicken embryo chorioallantoic membrane contact test, the contact time of the test solution with a mass percentage concentration of 3.125% is controlled at 5 min, and its irritation score is 0.00 with no vascular bleeding, no vascular dissolution, and no coagulation. In the in vitro cell toxicity test, the in vitro cell survival rate of fibroblasts and keratinocytes after 48 h of contact with the anti-aging cosmetic formulation is greater than or equal to 95%.

[0027] Preferably, the anti-aging cosmetic formulation has physicochemical stability. After being placed in a high-temperature environment of 40°C, a low-temperature environment of -10°C, and a strong light irradiation environment with a wavelength of 300nm to 400nm for 30 consecutive days, the purity of the mTOR inhibitor MTT-1 was found to be greater than or equal to 98% by high-resolution mass spectrometry and nuclear magnetic resonance spectroscopy. The anti-aging cosmetic formulation also maintained an emulsion state without crystal precipitation or discoloration.

[0028] Preferably, the anti-aging cosmetic formulation has different product form configurations: in the form of a face cream, the mass percentage of polyol in the anti-aging cosmetic formulation is 8.0% to 15.0%, and the apparent viscosity of the system is maintained in the range of 10 Pa·s to 20 Pa·s; in the form of a serum, the mass percentage of polyol in the anti-aging cosmetic formulation is 3.0% to 7.9%, and the apparent viscosity of the system is maintained in the range of 1 Pa·s to 5 Pa·s.

[0029] Example 1: In a leave-on cream system that regulates the facial epidermal cell environment and reshapes dermal cell activity, when the facial skin barrier is in an aging state with stagnant intrinsic lipid channels and reduced levels of type I and type III collagen in the dermis, traditional macrolide inhibitors, with their sterically hindered, highly polar, long-chain macrocyclic cores, struggle to penetrate the intrinsic stratum corneum barrier. Furthermore, directly increasing the dosage linearly or combining them with excessive penetration enhancers easily triggers local cytotoxic damage and skin barrier structure collapse. Additionally, introducing them into complex cosmetic formulations containing emulsifiers, stabilizers, emollients, and polyols often leads to thermodynamic compatibility degradation, causing active ingredients to crystallize and degrade. Failure manifests as compatibility barriers, resulting in transdermal barriers and compatibility issues when the intervention ingredient is transformed into a mild topical formulation. In a homogenizing device, a cosmetic matrix is ​​composed of 1.0 to 5.0 parts by weight of emulsifier, 0.5 to 3.0 parts by weight of stabilizer, 5.0 to 20.0 parts by weight of emulsifier, 8.0 to 15.0 parts by weight of polyol, and deionized water to a final volume of 100.0 parts. The emulsifiers are potassium cetyl phosphate and glyceryl stearate; the polyols are glycerin, butylene glycol, and propylene glycol; the stabilizers are xanthan gum and carbomer; and the emulsifiers are squalane, jojoba seed oil, and pentaerythritol tetraester. During blending and dispersion, the mass percentage concentration is 0.01% to 5.0%. The mTOR inhibitor MTT-1, a small molecule chromone derivative, was introduced into a cosmetic matrix. The material temperature was controlled between 35°C and 45°C, and further controlled within the range of 38°C to 42°C. The homogenization shear rate was controlled between 2000 rpm and 4000 rpm, and the stirring speed was controlled between 200 rpm and 500 rpm to disperse the components. A pH adjuster was added to adjust the system's pH to 5.5 to 6.5. The mechanical shear force generated by the homogenizer controlled the average particle size of the mTOR inhibitor MTT-1 in the cosmetic matrix to be between 100 nm and 500 nm, maintaining the apparent viscosity of the system between 10 Pa·s and 20 Pa·s. An anti-aging cosmetic formulation in the form of a face cream was prepared. The aforementioned chromone-type small molecule active substance has the chemical name 5-hydroxy-2-methyl-7-methoxychromone. This raw material is a known and publicly disclosed compound that can be obtained through commercially available channels or through chemical synthesis via the following route: using 2,4,6-trihydroxyacetophenone as the starting material, it is reacted with ethyl acetate in the presence of sodium metal catalysis to undergo a Claisen condensation reaction. The reaction product is cyclized under acidic conditions to obtain 5,7-dihydroxy-2-methylchromone. The 7-hydroxyl group is selectively methylated using dimethyl sulfate in a potassium carbonate and acetone system. After purification by recrystallization from ethanol, a refined solid powder with a purity of not less than 98% can be obtained.

[0030] Anti-aging cosmetic preparations in cream form were administered at a concentration of 0.5 mg / cm³. 2 Up to 2.0 mg / cm2 A single dose of the mTOR inhibitor MTT-1 is applied to the surface of the facial skin. Due to its planar conjugated molecular structure, MTT-1 penetrates the lipid channels of the stratum corneum and enters the epidermis and dermis. It diffuses in the extracellular matrix of the dermis and distributes around fibroblasts and keratinocytes, establishing a primary concentration enrichment zone around them. In practice, the establishment and control of the primary and secondary concentration enrichment zones are achieved through a refined facial micro-application procedure and quantitative penetration and diffusion management. During the initial application, a micro-application device is used to evenly spread the anti-aging cosmetic formulation onto the target skin area, with a constant single application dose of 1.0 mg / cm³. 2 Driven by mass transfer forces from the multi-layered lipid barrier of the epidermis, the formulation diffuses across the stratum corneum into the extracellular matrix of the superficial dermis via free diffusion. Within 4 to 6 hours after application, the concentration of free active components around fibroblasts and keratinocytes reaches a dynamic equilibrium, forming a first concentration enrichment zone with a baseline concentration. This is followed by a periodic, continuous dosing phase with two consecutive applications at a fixed 24-hour interval. Building upon the residual concentration in the first enrichment zone before complete metabolic decay, exogenous continuous mass flow induces a stepwise increase in concentration in the deep dermis. After 28 days of continuous application, the local enrichment of free active components reaches 1.5 to 2.3 times that of the first enrichment zone, thus constructing a highly saturated second concentration enrichment zone in the deep dermal tissue network. This process continues for 24 hours, continuously increasing the concentration of the active components. The anti-aging cosmetic formulation is applied to the surface of the facial skin, once or twice per cycle. This maintains the mTOR inhibitor MTT-1 in the dermis within the second concentration enrichment zone during a continuous administration cycle of 28 to 56 days. Through continuous administration, a progressive concentration buildup occurs within the skin tissue, making the concentration in the second concentration enrichment zone higher than that in the first concentration enrichment zone. This counteracts tissue damage during transdermal penetration of the anti-aging cosmetic formulation. Furthermore, by mitigating oxidative stress and inflammatory responses at low doses and blocking the phosphorylation activation state of the cascade axis of phosphatidylinositol 3-kinase, protein kinase B, and mammalian target of rapamycin at higher doses, the formulation releases the inhibition of the autophagy core complex and initiates the autophagy degradation process, clearing damaged intracellular components and denatured proteins, thereby restoring the proliferative vitality of skin cells in a state of aging stagnation.

[0031] The elastic modulus of the skin surface was periodically measured using a skin elasticity tester, and the rate of change of the elastic modulus over time was calculated. When the rate of change decreased to 0, the application cycle of the anti-aging cosmetic preparation was adjusted from twice every 24 hours to once every 24 hours. To clarify the specific calculation process and judgment logic for the aforementioned rate of change of elastic modulus over time decreasing to 0, in actual testing, the skin elasticity tester was used to perform multi-point sampling every 7 days on a fixed facial target area to obtain the apparent elastic modulus values ​​at each test point. The calculation involved subtracting the average elastic modulus of the previous test period from the average elastic modulus of the current test period, and then dividing by the average elastic modulus of the previous test period to obtain the weekly rate of change of elastic modulus for that period. When the weekly rate of change measured for three consecutive times was 0, the calculation was considered complete. Within a fluctuation range of 0.01% to 0.05%, or when the calculated weekly rate of change for the current period is negative, the control logic determines that the rate of change has decreased to 0, indicating that the collagen remodeling and rheological stiffness increase of the skin tissue have reached a saturation plateau. At this time, reducing the frequency of administration can avoid tissue overload and maintain a healthy skin elasticity. After anti-aging cosmetic preparations are continuously stored for 30 days in environments with high temperature (40℃), low temperature (-10℃), and strong light irradiation with wavelengths of 300nm to 400nm, the purity of the mTOR inhibitor MTT-1 inside is greater than or equal to 98%, and it remains in an emulsion state without crystal precipitation or discoloration. In the chicken embryo chorioallantoic membrane test with a contact time of 5 minutes and a mass percentage concentration of 3.125%, its stimulation score is 0.00 and without vascular bleeding, vascular dissolution, or coagulation; in the in vitro cytotoxicity test with a contact time of 48 hours, the survival rate of fibroblasts and keratinocytes was greater than or equal to 95%, increasing the content of type I and type III collagen in the dermis; the dispersed phase particle size of the mTOR inhibitor MTT-1 in anti-aging cosmetic formulations is in the range of 100nm to 500nm, maintaining a thermodynamically uniform dispersion of inactive components in an alternating temperature environment of 40℃ to -10℃, and maintaining continuous penetration of the extracellular matrix of the dermis during continuous residence on the facial skin surface, maintaining autophagy activity in the second concentration enrichment zone, and keeping the expression levels of type I and type III collagen in facial skin tissue within the healthy range; in order to elucidate the microscopic dispersion and stabilization mechanism of the planar conjugation characteristics of chromone small molecule active substances in the lipid interface, the bridging mechanism of weak intermolecular interactions is introduced here. To demonstrate its physical feasibility, although the planar conjugated backbone exhibits a potential stacking tendency, the molecular structure selected in this invention contains specific hindrance substituents that can form an interlaced non-covalent network at the complex interface of topical formulations. When the active substance is introduced into a formulation system containing emulsifiers, stabilizers, emollients, and polyols, strong dispersion forces and electrostatic induction effects are generated between the planar conjugated system of the molecules, the hydrophobic long-chain tails of the emulsifiers, and the ester backbone of the emollients. This microscopic amphiphilic spatial orientation fit weakens the symmetric stacking energy of the active molecules themselves. During transdermal penetration across the lipid channels of the stratum corneum, this weakly interacting network undergoes reversible dissociation and reconstruction driven by topical shear forces and body temperature, allowing small molecules to spread uniformly in the epidermal lipid bilayer interface as monomolecules or micro-associations. This maintains thermodynamic uniformity while smoothly penetrating the inherent barrier and delivering uniformly into the dermal tissue.

[0032] Example 2: When the in vitro skin tissue culture platform operates in a constant-temperature chamber simulating the high-resistivity mass flow resistance and room temperature environment of facial epidermis, the basic physicochemical dataset obtained by an automated tissue sampling and analysis system with a temperature control accuracy of 0.1℃ and a shear force sensor sampling frequency of 100Hz constitutes the data source for the entire experiment. The core process parameter, the homogeneous shear rate, needs to be set based on the measurement and analysis of the local phase evolution characteristics of the emulsion particles. The engineering challenge in setting this parameter lies in balancing the mechanical shear energy input with the engineering constraints of damaging and differentiating the matrix emulsifier interface film. When the target cosmetic system needs to pass through relatively polar lipid channels in the stratum corneum... To ensure that the average particle size of the active ingredients remains within the transdermal release window of 100 nm to 500 nm, the homogenization shear rate tends to be at its upper limit of 4000 rpm when dealing with pastes with higher-than-normal viscosity, and at its lower limit of 2000 rpm when dealing with low-viscosity fluids. For a cosmetic matrix consisting of 3.0 parts by weight of emulsifier, 1.5 parts by weight of stabilizer, 12.0 parts by weight of emulsifier, 10.0 parts by weight of polyol, and 73.5 parts by weight of deionized water, the above adjustment rules were applied to determine the homogenization shear rate as 3000 rpm, the stirring speed as 350 rpm, and the material temperature as 40°C.

[0033] To confirm the synergistic effect of the complete component combination and the boundary effect of the corresponding parameter range, a multidimensional control system was constructed, including sample group 1, sample group 2, sample group 3 of this invention, partially missing control group 1, partially missing control group 2, out-of-range control group 1, and out-of-range control group 2. The raw test signal stream from the optical tracking sensor contained a background baseline noise fluctuation of 5.3% due to ambient light and thermal scattering. The data processing unit used a mean filtering algorithm with a sliding window length of 10 cycles to process the raw test signal stream. The background baseline noise fluctuation amplitude is suppressed to below 0.4%, and a high-fidelity smooth feature dataset is output. In this control system, sample group one of the present invention uses a cosmetic matrix composed of a chromone small molecule mTOR inhibitor MTT-1 with a lower limit mass percentage concentration of 0.01%, combined with 1.0 part emulsifier, 0.5 part stabilizer, 5.0 part emollient, 8.0 part polyol, and 85.5 parts deionized water, and is processed at 35°C and a homogeneous shear rate of 2000 rpm. Sample group two of the present invention uses a mass percentage concentration with a median value of... The matrix consisted of 1.0% mTOR inhibitor MTT-1, combined with the above-mentioned parts by weight of emulsifier 3.0 parts, stabilizer 1.5 parts, emollient 12.0 parts, polyol 10.0 parts, and deionized water, and was processed at 40°C and a homogeneous shear rate of 3000 rpm. Sample group three of this invention used a matrix consisting of 5.0% mTOR inhibitor MTT-1 at the upper limit of its mass percentage concentration, combined with emulsifier 5.0 parts, stabilizer 3.0 parts, emollient 20.0 parts, polyol 15.0 parts, and deionized water. Processing was carried out at a temperature of 45℃ and a homogeneous shear rate of 4000rpm. The partial deletion control group 1 omitted the mTOR inhibitor MTT-1 in the matrix, the partial deletion control group 2 used rapamycin at a mass percentage concentration of 1.0% to replace the mTOR inhibitor MTT-1, the out-of-range control group 1 reduced the mass percentage concentration of the mTOR inhibitor MTT-1 to 0.005% and set the processing temperature to 30℃, and the out-of-range control group 2 increased the mass percentage concentration of the mTOR inhibitor MTT-1 to 6.0% and set the processing temperature to 50℃.

[0034] Analysis of the smoothed feature dataset revealed that the dispersion characteristics of anti-aging cosmetic formulations exhibited a clear nonlinear trend in the boundary of physical properties and the inflection point of performance changes. After undergoing alternating high-temperature (40℃) and low-temperature (-10℃) storage cycles for 30 days, the average particle size of sample group two remained stable at 241.6 nm, and the apparent viscosity of the system remained at 14.32 Pa·s, without any crystal precipitation or phase separation. In contrast, the out-of-range control group two, exceeding the upper limit, underwent an irreversible phase transition after the same temperature storage, with the system agglomerating and the apparent viscosity drastically decreasing to 3.15 Pa·s. This phenomenon is consistent with the trend of solute... When the concentration exceeded the thermodynamic critical stability window, the local phase evolution law of the charge repulsion barrier at the interface between potassium cetyl phosphate and glyceryl stearate was disrupted, confirming that the upper limit of the concentration constituted the stability boundary for maintaining the thermodynamic homogeneity of the formulation. Simultaneously, the average particle size of the control group 1 (below the lower limit) increased to 612.4 nm, significantly exceeding the transmembrane permeation scale of dermal lipid channels, causing the active ingredient to remain on the skin surface and unable to accumulate in the dermis. In terms of synergistic verification of biological effects, the expression level index of type I collagen in the partially deficient control group 1 (lacking the active ingredient) was only 1.02, while... Although the partially rapamycin-deficient control group II showed a type I collagen expression level index of 1.43, it exhibited a tissue stimulation score as high as 3.82 in the chicken embryo chorioallantoic membrane test, accompanied by capillary dissolution. In contrast, the type I collagen expression level index of the complete technical solution of this invention group II increased to 2.84, and the type III collagen expression level index increased to 2.65, while its tissue stimulation score remained at 0.00. This performance leap, far exceeding the linear summation of the individual components, confirms that the cosmetic matrix with chromone planar conjugated structure and particle size distribution has nonlinear transdermal synergistic and autophagy-stimulating effects. The active synergistic effect and continuous monitoring of characteristic data chain construct a clear physical causal closed loop, indicating that under the constraints of cosmetic formulation and variable temperature blending process, the chromone small molecule mTOR inhibitor MTT-1 with a mass percentage concentration of 0.01% to 5.0% can maintain the autophagy clearance pathway in the dermal tissue and reverse the aging phenotype without damaging the skin cell structure. When the in vitro aging skin cell model was exposed to sample group II of the present invention, the in vitro cell survival rate of its fibroblasts remained at 97.64% after continuous exposure for 48 hours, and the DNA replication rate in the cell nucleus was increased by 2% compared with the untreated group.The 45-fold increase confirms that the parameter combination defined in this invention constitutes an optimized working window that balances the thermodynamic stability, transdermal diffusion flux, and fibroblast proliferation safety of the topical composition. These test results directly corroborate the substantial effectiveness of the mTOR inhibitor MTT-1 in improving collagen expression and ensuring skin tissue tolerance in anti-aging cosmetic applications. The dispersed phase particle size of the mTOR inhibitor MTT-1 in the anti-aging cosmetic formulation is in the range of 100nm to 500nm. It maintains a thermodynamically uniform dispersion of inactive components in an alternating temperature environment of 40℃ to -10℃, and maintains continuous penetration into the extracellular matrix of the dermal layer during continuous residence on the facial skin surface, maintaining autophagy activity in the second concentration enrichment zone, and keeping the expression levels of type I and type III collagen in facial skin tissue within the healthy range.

[0035] Example 3: This example combines Figures 1 to 2 Instructions on the application of the mTOR inhibitor MTT-1 in anti-aging cosmetics, such as... Figure 1 As shown, mTOR inhibitor MTT-1 with a mass percentage concentration of 0.01% to 5.0% is mixed with a cosmetic matrix containing emulsifiers, stabilizers, emollients, polyols, and deionized water and fed into a homogenizing device for blending and dispersion to introduce the mTOR inhibitor MTT-1 into the cosmetic matrix. During this process, the homogenization parameter control module controls the material temperature at 35-45℃, the homogenization shear at 2000-4000 rpm, and the stirring at 200-500 rpm. Simultaneously, the pH adjustment module adds a pH adjuster to adjust the system pH to 5.0 to 7.5. After the above steps, the anti-aging cosmetic formulation with the blended dispersion of all components is output. This is then applied to the surface of human facial skin at a single dose of 0.5 mg / cm³. 2 Up to 2.0 mg / cm 2 Transdermal penetration occurs, allowing the drug to diffuse through lipid channels in the stratum corneum into the dermis. This establishes an extracellular matrix microenvironment surrounding fibroblasts and keratinocytes, creating a first concentration enrichment zone around the cells. Continuous cyclical administration is then performed every 24 hours, with 1 to 2 applications per cycle. This generates a progressive concentration additive effect, inducing continuous drug administration within the skin tissue and establishing a second concentration enrichment zone in the dermis that is higher than the first concentration enrichment zone. This second concentration enrichment zone, on the one hand, triggers a tissue depletion countermeasure mechanism to offset tissue depletion during transdermal penetration of anti-aging cosmetics, and on the other hand, increases dermal collagen levels, thereby increasing the content of type I and type III collagen.

[0036] like Figure 2As shown, the initial active component, with a mass percentage concentration of 0.01% to 5.0%, is in a free ligand state. After transfer, it is converted into a homogeneous blended dispersion state with a pH value of 5.0 to 7.5 and stable viscosity, namely the protonated equilibrium formulation state. It then transfers to the stratum corneum barrier diffusion state, a transdermal penetration relay state, to overcome the transdermal energy dissipation damping index, forming a first concentration enrichment state with an initial distribution pattern of extracellular matrix surrounding fibroblasts and keratinocytes. It further transfers to a second concentration enrichment state with a deep dermal layer superposition pattern, inducing continuous drug delivery superposition. This second concentration enrichment state will transfer to the tissue wear and clearance state to cope with tissue wear during transdermal penetration and refeed back to itself. This second concentration enrichment state finally transfers to the collagen remodeling state to achieve the final biological effect of enhancing type I and type III collagen.

[0037] Example 4: When the system faces a low transdermal throughput scenario where the thickness of the facial epidermal stratum corneum increases to the limit and the inherent lipid channels are stagnant, the chromone small molecule mTOR inhibitor MTT-1, which is processed in the homogenizing equipment at the absolute lower limit of 0.01%, faces mass transfer resistance due to the weak driving force of the low concentration gradient, which is easily blocked by the high resistance of the epidermal mass flow. Furthermore, if the material is mixed in an environment where the material temperature is set at the processing lower limit of 35°C, the matrix component will experience a sharp increase in viscosity and stability problems due to the early phase separation of the emulsion particle nuclei as it approaches its thermodynamic solubility inflection point. This leads to local mass loss of active molecules during the compound diffusion and hinders the reversal of the autophagy phenotype of fibroblasts and keratinocytes in the dermis.

[0038] To calibrate the control path of the preparation process under extreme boundary conditions and eliminate process uncertainties, the system defines the initial state specifications at the input end. The homogenizer is defined as having a zoned temperature control accuracy of 0.1℃ and a mechanical stirrer with a torque range covering 0.1 N·m to 5.0 N·m. The cosmetic matrix consists of accurately weighed emulsifier (1.0 part), stabilizer (0.5 parts), emollient (5.0 parts), polyol (3.0 parts), and deionized water to a total of 100.0 parts. The mTOR inhibitor MTT-1 is introduced into the cosmetic matrix at a mass percentage concentration of 0.01%, the material temperature is maintained at 35℃, and the mechanical stirrer is started at a stirring speed of 200 rpm. The system provides interfacial wetting power, increasing the homogenization shear rate to a boundary value of 2000 rpm to counteract the shear resistance generated by the high-viscosity matrix. Under these conditions, a pH regulator is added to the system at a constant rate to maintain the pH value at the absolute lower limit of 5.0. This controls the specific protonation equilibrium state of the chromone-based small molecule mTOR inhibitor MTT-1 within the cosmetic matrix. Furthermore, the fluid shear force generated by the homogenizing device controls the apparent average particle size of the active ingredient within a discrete boundary envelope of 480 nm to 495 nm, thus stabilizing the apparent viscosity of the anti-aging cosmetic formulation within the range of 18.5 Pa·s to 19.8 Pa·s.

[0039] To quantify the energy loss and structural resistance during the penetration of active components through the aforementioned stagnant epidermal barrier, this invention combines the principle of hydrodynamic mass transfer resistance, defining the mechanical obstruction of small molecule diffusion by lipid channels in the stratum corneum per unit area as the transdermal energy dissipation damping index. In a continuous input evolution test on ex vivo skin barrier samples, when the stratum corneum thickness measured at the input end was 35 μm and the relative density of lipid channels was low, the baseline value of the transdermal energy dissipation damping index was determined to be 12.65 dimensionless units by measuring the mass flow rate through the membrane and combining it with Fick's diffusion law for theoretical derivation and calculation. Under this extreme fault-tolerant resistance environment, the above-prepared anti-aging cosmetic formulation was applied at 0.5 mg / cm³. 2Low-dose application of the boundary layer to the surface of isolated skin barrier samples revealed that, due to the smaller molecular geometry of the planar conjugated structure compared to the limiting transmembrane threshold of lipid channels, the mTOR inhibitor MTT-1 overcame the blocking effect of the transdermal energy dissipation damping index and penetrated the stratum corneum at a constant mass transfer rate, distributing around fibroblasts and keratinocytes and establishing a first concentration enrichment zone. Under the restriction of low-frequency dosing with a 24-hour cycle and only one application per cycle, a second concentration enrichment zone was induced after 28 days of continuous maintenance. The expression levels of type I collagen and type III collagen in fibroblasts, measured by an automated cold light charge-coupled device imaging scanner, rebounded to 2.15 and 1.98, respectively, and the in vitro cell viability remained at 96.2%. This indicates that even under extreme conditions where the material concentration, processing temperature, and pH value are all at absolute lower limits, the anti-aging cosmetic formulation can still maintain stable transdermal diffusion flux and safety through protonation adaptive regulation and a specific dispersion phase, clearing autophagy blockade products and promoting the exchange of type I and type III collagen in facial skin tissue. The expression level of the original protein remained within a healthy range. Regarding the aforementioned transdermal energy dissipation damping index, the baseline value of 12.65 has engineering significance and boundary limitations. Determining its lower and upper limits is instructive for evaluating drug delivery systems in extremely low transdermal flux scenarios. When this index is below 5.0 dimensionless units, it indicates a weak stratum corneum barrier or that the inherent channels are in a highly open state. In this case, active small molecules will undergo instantaneous over-penetration without resistance, easily breaching the local safety window and causing cytotoxic side effects. Conversely, when this index is above... At 15.0 dimensionless units, the stratum corneum is abnormally thickened or in a state of extreme high resistance mass transfer. At this time, the external mass transfer resistance is too large, causing the active molecules in the formulation to be completely stagnant outside the lipid bilayer and unable to accumulate in the dermis to the minimum critical concentration required for autophagy regulation. When facing an extreme environment with an index of 12.65, this invention maintains a stable transdermal diffusion flux by limiting the specific particle size envelope and protonated phase of the formulation, ensuring that the system can still reproduce the anti-aging regulatory pathway even at the upper limit of the engineering boundary.

[0040] Example 5: When the system faces fluctuations in rheological shear resistance of different batches of matrix raw materials, to avoid technical problems such as uneven dispersion of emulsified particles and excessive viscosity of the system caused by batch differences in raw materials, the homogenizing equipment initiates pre-kinetic calibration before introducing the active solute. This involves applying a gradient of increasing mechanical shear force to the weighed cosmetic matrix composed of emulsifier, stabilizer, emollient, polyol, and deionized water. The feedback torque resistance data within a preset speed range is collected by a fluid tension sensor at the end of the stirring shaft. The control chip compares this data with the standard viscosity-rheological curve stored in the memory to determine the reference rheological coefficient of the current batch of material. Then, the initial compensation ratio of the homogenization shear rate and stirring speed is calculated and corrected online. Specifically, the aforementioned standard viscosity-rheological curve stored in the memory is determined by… The benchmark dataset for the nonlinear variation of feedback torque with rotational speed is measured under test conditions of 39℃ and shear rate gradually increasing from 100 rpm to 5000 rpm. The benchmark rheological coefficient of the current batch of material refers to the proportionality constant obtained by fitting the actual feedback torque curve collected by the fluid tension sensor under the same shear gradient with the standard viscosity rheological curve using the least squares method. When this coefficient deviates from the nominal value of 1.0, it indicates that the current batch of matrix raw material has generated excess flow resistance due to fluctuations in rheological properties. During online calculation and correction, the control chip multiplies the deviation of this coefficient by a preset process sensitivity matrix, thereby quantitatively outputting the compensation gain of homogeneous shear rate and stirring speed, and realizing constant control of rheological state across batches.

[0041] The homogenization shear rate of the homogenizer was set to 2500 rpm and the stirring speed to 300 rpm based on the reference rheological coefficient. A 1.0% (w / w) concentration of the chromone-based small molecule mTOR inhibitor MTT-1 was added dropwise into the cosmetic matrix. The material temperature was maintained at 39℃ and the mixture was blended for 45 min. The dropwise flow rate of the pH regulator was finely adjusted online to stabilize the pH of the system at 6.2. Under these parameters, the anti-aging cosmetic formulation remained in an emulsified phase. The particle size of the dispersed phase of the mTOR inhibitor MTT-1 was measured to be in the range of 210 nm to 235 nm using a particle size analyzer. The apparent viscosity of the system remained stable at 14.5 Pa·s. The expression levels of type I collagen and type III collagen around fibroblasts and keratinocytes in the dermis were maintained at 2.35 and 2.18, respectively.

[0042] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the present invention can be implemented in other specific forms without departing from the spirit or essential characteristics of the present invention.

[0043] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.

Claims

1. The application of an mTOR inhibitor, MTT-1, in anti-aging cosmetics, characterized in that, Includes the following steps: Step S1: In a homogenizing device, an mTOR inhibitor MTT-1 with a mass percentage concentration of 0.01% to 5.0% is introduced into the cosmetic matrix. The material temperature is controlled at 35°C to 45°C, the homogenization shear rate is controlled at 2000 rpm to 4000 rpm, and the stirring speed is controlled at 200 rpm to 500 rpm. The components are blended and dispersed, and a pH adjuster is added to adjust the pH of the system to 5.0 to 7.5 to obtain an anti-aging cosmetic formulation. The cosmetic matrix is ​​composed of emulsifiers, stabilizers, emollients, polyols, and deionized water. Step S2, dissolve the anti-aging cosmetic preparation at 0.5 mg / cm³. 2 Up to 2.0 mg / cm 2 A single dose applied to the surface of the facial skin penetrates the lipid channels of the stratum corneum and diffuses into the dermis, allowing the mTOR inhibitor MTT-1 to diffuse in the extracellular matrix microenvironment of the dermis and surround fibroblasts and keratinocytes, establishing a first concentration enrichment zone around fibroblasts and keratinocytes. Step S3 involves continuously applying the anti-aging cosmetic preparation to the surface of the facial skin in a 24-hour cycle, applying it once or twice per cycle. Through continuous administration, a progressive concentration accumulation is induced within the skin tissue, establishing a second concentration enrichment zone in the dermis that is higher than the first concentration enrichment zone. This counteracts tissue loss during transdermal penetration of the anti-aging cosmetic preparation and increases the content of type I and type III collagen in the dermis.

2. The application of the mTOR inhibitor MTT-1 according to claim 1 in anti-aging cosmetics, characterized in that, In step S1, the cosmetic matrix comprises the following components by weight: 1.0 to 5.0 parts of emulsifier, 0.5 to 3.0 parts of stabilizer, 5.0 to 20.0 parts of emollient, 3.0 to 15.0 parts of polyol, and deionized water to make up to 100.0 parts; during the blending and dispersion, the material temperature is controlled within the range of 38°C to 42°C, and the pH of the system is adjusted to 5.5 to 6.5 to improve the thermodynamic compatibility of the anti-aging cosmetic formulation in alternating hot and cold environments.

3. The application of the mTOR inhibitor MTT-1 according to claim 1 in anti-aging cosmetics, characterized in that, Step S2 includes the following sub-steps: Step S21, applying the anti-aging cosmetic preparation to the surface of the human face skin, so that the mTOR inhibitor MTT-1 in the anti-aging cosmetic preparation can penetrate the stratum corneum of the skin surface and enter the epidermis and dermis. Step S22 allows the mTOR inhibitor MTT-1, which has entered the dermis, to diffuse in the extracellular matrix of the dermis and distribute around fibroblasts and keratinocytes, establishing a first concentration enrichment zone.

4. The application of the mTOR inhibitor MTT-1 according to claim 1 in anti-aging cosmetics, characterized in that, The emulsifiers include potassium cetyl phosphate and glyceryl stearate, the polyols include glycerin, butylene glycol and propylene glycol, the stabilizers include xanthan gum and carbomer, and the emollients include squalane, jojoba seed oil and pentaerythritol tetraester; in step S1, the homogenization shear rate is controlled at 2000 rpm to 4000 rpm, and the average particle size of the mTOR inhibitor MTT-1 in the cosmetic matrix is ​​controlled in the range of 100 nm to 500 nm.

5. The application of the mTOR inhibitor MTT-1 according to claim 1 in anti-aging cosmetics, characterized in that, Step S3 includes the following sub-steps: Step S31, applying the anti-aging cosmetic preparation to the surface of the facial skin continuously for 24 hours, applying it once or twice per cycle, so that the mTOR inhibitor MTT-1 in the dermis is maintained in the second concentration enrichment zone during the continuous administration period of 28 days to 56 days; Step S32, under the effect of the concentration in the second concentration enrichment zone, increasing the levels of type I collagen and type III collagen in the dermis.

6. The application of the mTOR inhibitor MTT-1 according to claim 1 in anti-aging cosmetics, characterized in that, During the continuous application of anti-aging cosmetic formulations to the surface of facial skin, the elastic modulus of the skin surface is periodically measured using a skin elasticity tester. The rate of change of elastic modulus over time is calculated. When the rate of change decreases to 0, the application cycle of the anti-aging cosmetic formulations is adjusted from twice every 24 hours to once every 24 hours.

7. The application of the mTOR inhibitor MTT-1 according to claim 1 in anti-aging cosmetics, characterized in that, The anti-aging cosmetic formulation exhibits safety against chicken embryo chorioallantoic membrane and in vitro cell safety. In the chicken embryo chorioallantoic membrane contact test, the contact time of the test solution with a mass percentage concentration of 3.125% was controlled at 5 min, and the irritation score was 0.00 with no vascular bleeding, no vascular dissolution, and no coagulation. Furthermore, in the in vitro cell toxicity test, the in vitro cell survival rate of fibroblasts and keratinocytes after 48 h of contact with the anti-aging cosmetic formulation was greater than or equal to 95%.

8. The application of the mTOR inhibitor MTT-1 according to claim 1 in anti-aging cosmetics, characterized in that, The anti-aging cosmetic formulation exhibits physicochemical stability. After being placed in a high-temperature environment of 40℃, a low-temperature environment of -10℃, and a strong light irradiation environment with a wavelength of 300nm to 400nm for 30 consecutive days, the purity of the mTOR inhibitor MTT-1 was found to be greater than or equal to 98% by high-resolution mass spectrometry and nuclear magnetic resonance spectroscopy. Furthermore, the anti-aging cosmetic formulation maintained an emulsion state without crystal precipitation or discoloration.

9. The application of the mTOR inhibitor MTT-1 according to claim 1 in anti-aging cosmetics, characterized in that, Anti-aging cosmetic formulations have different product form configurations: in cream form, the mass percentage of polyols in the anti-aging cosmetic formulation is 8.0% to 15.0%, and the apparent viscosity of the system is maintained in the range of 10 Pa·s to 20 Pa·s; in serum form, the mass percentage of polyols in the anti-aging cosmetic formulation is 3.0% to 7.9%, and the apparent viscosity of the system is maintained in the range of 1 Pa·s to 5 Pa·s.

Images